2 results
Approved WMOPending
To assess the efficacy of inhaled RVT-1601 in comparison with placebo following 12 weeks of treatment
Approved WMOPending
Part 1 (Dose Escalation) - to identify the recommended Phase 2 dose(s) and schedule(s) to be safe for JNJ-79635322. Part 2 (Dose Expansion) is to characterize the safety and tolerability of JNJ-79635322 at the RP2D(s).